Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to capitalize on momentum in the field.
The Series C marks the biotech’s first venture investment in about six years; it last raised a $49 million Series B in late…
Click here to view original post
